• Yonggeng Zhang, Shu Sun, and Song Yi.
• Department of Cardiology, Yichun People's Hospital, Jiangxi, China.
• Medicine (Baltimore). 2021 Jun 25; 100 (25): e26396e26396.

BackgroundCardiovascular diseases have become a prominent threat to public health and quality of life. In recent years, some studies have reported that ivabradine can improve the cardiac function and prognosis of patients with acute myocardial infarction (AMI). Therefore, we perform a protocol for systematic review and meta-analysis to evaluate the efficacy of ivabradine for treating AMI.MethodsThis protocol of systematic review and meta-analysis has been drafted under the guidance of the preferred reporting items for systematic reviews and meta-analyses protocols. We will search PubMed, Cochrane Library, Embase, Web of Science, and Medline databases for relevant studies. In addition, we will also collect 4 databases of China: China National Knowledge Infrastructure, China Biomedical Literature Database, China Science Journal Database, and Wan-fang Database. Risk of bias will be assessed using the Cochrane Handbook risk of bias assessment tool version (V.5.1.0). We will use STATA 16.0 software (Stata Corporation, College Station, TX) to perform data analysis.ResultsThe results of this systematic review and meta-analysis will be published in a peer-reviewed journal.ConclusionWe hypothesized that ivabradine can reduce the resting heart rate and improve heart function in patients with AMI.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

32 keywords...

hide…